698-P: Glycemic Improvement in 11,273 Adults with Type 1 Diabetes (T1D) Using the Omnipod Insulin Management System over First 90 Days of Use
2021; American Diabetes Association; Volume: 70; Issue: Supplement_1 Linguagem: Inglês
10.2337/db21-698-p
ISSN1939-327X
AutoresGrazia Aleppo, Daniel J. DeSalvo, Felipe Lauand, Lauren M. Huyett, JAY JANTZ, Albert Y. Chang, Todd Vienneau, Trang T. Ly,
Tópico(s)Diabetes and associated disorders
ResumoReal-world evidence describing clinical outcomes in people with T1D using various devices is important to support decision-making. This retrospective study characterized patient-reported clinical outcomes in adults in the United States with T1D before (baseline) and 90 days after (follow-up) the initiation of a tubeless insulin pump (Omnipod® or Omnipod DASH® Insulin Management System). The primary outcome was change in self-reported HbA1c level from baseline to follow-up. Secondary outcomes were change in self-reported total daily dose (TDD) of insulin and self-reported frequency of hypoglycemic events (HE) per week (#/week <70 mg/dL). Outcomes were assessed overall and by prior treatment modality (MDI or CSII) and age group. Patients were aged 40.3±15.2y (mean±SD) and 59.1% female (Table). The overall change in self-reported HbA1c at follow-up was -0.8±1.5% (p<0.0001). Overall change in TDD of insulin was -10.5±20.6U/d (p<0.0001) and the self-reported HE frequency decreased significantly by -1.4±3.0 episodes per week (p<0.0001). Reductions in HbA1c, TDD and HE were seen regardless of prior treatment or age group. In this large cohort of adults with T1D, initiation of a tubeless insulin pump was associated with significant reductions in HbA1c, TDD of insulin, and number of HE after 90 days of use compared to prior MDI and CSII treatments and across age groups.View largeDownload slideView largeDownload slide DisclosureG. Aleppo: Consultant; Self; Dexcom, Inc., Insulet Corporation, Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk. D. Desalvo: Consultant; Self; Insulet Corporation, Research Support; Self; Insulet Corporation, Speaker’s Bureau; Self; Dexcom, Inc. F. Lauand: Employee; Self; Insulet Corporation. L. M. Huyett: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. J. Jantz: Employee; Self; Insulet Corporation. A. Chang: Employee; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. T. Ly: Employee; Self; Insulet Corporation.FundingInsulet Corporation
Referência(s)